China Feihe stock holds after 2025 profit and 2024 revenue growth

China Feihe stock remains tied to a business that reported RMB 21.2 billion in revenue for 2024, up 6.2% from 2023, while 2025 profit attributable to owners rose to RMB 7.4 billion. The company also reported a gross margin of 62.5% in 2024, giving investors a clearer read on how volume and pricing flowed through the dairy infant formula group.

Revenue up 6.2%

China Feihe, the Hong Kong-listed infant formula maker, said 2024 revenue reached RMB 21.2 billion and grew 6.2% year on year. That is a useful comparison because it shows the top line still expanded even as the category remained competitive.

The same 2024 report put gross margin at 62.5%, which indicates the company kept a high margin profile across the year. Profit attributable to owners reached RMB 7.4 billion in 2025, a concrete earnings figure that supports the stock beyond a simple sales story.

Profit at RMB 7.4 billion

The profit number matters because it gives a second anchored data point after revenue. Together with RMB 21.2 billion of 2024 sales and 62.5% gross margin, it suggests the company ended the period with a strong operating base rather than only a one-off revenue lift.

For market readers, the comparison that stands out is the 6.2% revenue increase against the prior year. A company that can add revenue and preserve a margin above 60% is usually watched more closely than one relying on top-line growth alone.

Infant formula still drives

Feihe's infant formula franchise remains the core product line behind the reported numbers, and the 2024 revenue and margin data show that the category still matters to the companys earnings power. For a stock like China Feihe, that product concentration makes every change in sales mix and profitability worth tracking.

The stock story is therefore less about a single day move and more about whether the company can keep converting revenue into profit. The 2025 profit figure of RMB 7.4 billion and the 2024 gross margin of 62.5% both point in that direction.

Market view stays numeric

China Feihe stock closed around HKD 4.10 as of 23 July 2026, giving the market a live reference point against the reported operating figures. The combination of HKD 4.10, RMB 21.2 billion revenue, and RMB 7.4 billion profit is the clearest set of numbers to frame the shares today.

That mix leaves the debate centered on execution rather than narrative. Revenue rose 6.2% in 2024, gross margin held at 62.5%, and profit attributable to owners reached RMB 7.4 billion in 2025, which is enough to keep the stock anchored to fundamentals.

Company profile

China Feihe is a major infant formula producer in China, and the current numbers underline why the business line remains the central investment lens. The company has built its reporting around growth, margin, and earnings quality, and those three metrics still define the stock narrative.

Share price reference

China Feihe stock was priced at HKD 4.10 as of 23 July 2026 on its Hong Kong market reference point. That price sits alongside the 2024 revenue of RMB 21.2 billion and the 2025 profit of RMB 7.4 billion in the current data set.